Company Announcement no. 24/2007
To: OMX Nordic Exchange Hørsholm, Denmark, September 30, 2007
Total number of voting rights and size of share capital in LifeCycle Pharma A/S
as of September 30, 2007
Summary: Total number of voting rights and size of share capital in LifeCycle
Pharma A/S as of September 30, 2007.
In accordance with Section 6 of the Danish Statutory Order on Issuers'
Disclosure Obligations, LifeCycle Pharma A/S is required to publish the total
number of voting rights and the size of the share capital in LifeCycle Pharma
A/S at the end of each calendar month where there has been a change.
The share capital in LifeCycle Pharma A/S consists of one class of shares and as
of 30 September 2007 the share capital amounts to DKK 31,770,705 divided into
31,770,705 shares of DKK 1 each and 31,770,705 votes.
About LifeCycle Pharma A/S ("LCP A/S"):
LCP A/S, headquartered in Hørsholm, Denmark, is an emerging specialty
pharmaceutical company focused on developing and commercializing a portfolio of
innovative products in therapeutic areas such as cholesterol management,
hypertension, organ transplantation and autoimmune diseases. LCP's proprietary
MeltDose® technology, offers lower dosing, reduced side effects, improved safety
and patient compliance, and reduced product development costs and times.
LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and
hypertriglyceridemia, is LCP's first FDA approved product (approved in August
2007). LCP is listed on the OMX Nordic Exchange under the trading symbol
(OMX:LCP). For further information, please visit www.lcpharma.com.
Contact:
Francesca M. DeMartino
Director, Investor Relations & Corporate Communications
(201) 633-4729
FDM@lcpharma.com
---oo0oo---
Total number of voting rights and size of share capital in LifeCycle Pharma A/S as of September 30, 2007
| Source: Veloxis Pharmaceuticals A/S
Attachments
